Lipidomics and Transcriptomics Differ Liposarcoma Differentiation Characteristics That Can Be Altered by Pentose Phosphate Pathway Intervention
Abstract
:1. Introduction
2. Results
2.1. Lipidomics Reveals the Lipid Alterations between WDLPS and DDLPS
2.2. Transcriptome Reveals That WDLPS and DDLPS Correlate to Different Adipocytic Differentiation Stages
2.3. Transcriptomic Analysis Reveals the Upregulation of Pentose Phosphate Pathway in WDLPS
2.4. Inhibition of Pentose Phosphate Pathway Promotes Cell Proliferation and Invasion of Liposarcoma
3. Discussion
4. Materials and Methods
4.1. Sample Collection
4.2. Ex Vivo Cell Culture
4.3. Cell Proliferation Assay
4.4. Transwell Invasion Assay
4.5. SVF Differentiation
4.6. Lipid Extraction
4.7. Lipidomic Analysis
4.8. RNA Sequencing
4.9. Metabolic Similarity between LPS and SVF
4.10. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sbaraglia, M.; Bellan, E.; Dei Tos, A.P. The 2020 WHO Classification of Soft Tissue Tumours: News and perspectives. Pathologica 2021, 113, 70–84. [Google Scholar] [CrossRef]
- Tyler, R.; Wanigasooriya, K.; Taniere, P.; Almond, M.; Ford, S.; Desai, A.; Beggs, A. A review of retroperitoneal liposarcoma genomics. Cancer Treat. Rev. 2020, 86, 102013. [Google Scholar] [CrossRef] [PubMed]
- Lee, A.T.J.; Thway, K.; Huang, P.H.; Jones, R.L. Clinical and Molecular Spectrum of Liposarcoma. J. Clin. Oncol. 2018, 36, 151–159. [Google Scholar] [CrossRef] [PubMed]
- Thway, K. Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review. Semin. Diagn. Pathol. 2019, 36, 112–121. [Google Scholar] [CrossRef] [PubMed]
- Raut, C.P.; Callegaro, D.; Miceli, R.; Barretta, F.; Rutkowski, P.; Blay, J.Y.; Lahat, G.; Strauss, D.C.; Gonzalez, R.; Ahuja, N.; et al. Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. Clin. Cancer Res. 2019, 25, 2664–2671. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dalal, K.M.; Kattan, M.W.; Antonescu, C.R.; Brennan, M.F.; Singer, S. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann. Surg. 2006, 244, 381–391. [Google Scholar] [CrossRef] [PubMed]
- Zhuang, A.; Wu, Q.; Tong, H.; Zhang, Y.; Lu, W. Development and Validation of a Nomogram for Predicting Recurrence-Free Survival of Surgical Resected Retroperitoneal Liposarcoma. Cancer Manag. Res. 2021, 13, 6633–6639. [Google Scholar] [CrossRef]
- Italiano, A.; Toulmonde, M.; Cioffi, A.; Penel, N.; Isambert, N.; Bompas, E.; Duffaud, F.; Patrikidou, A.; Lortal, B.; Le Cesne, A.; et al. Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival. Ann. Oncol. 2012, 23, 1601–1607. [Google Scholar] [CrossRef]
- Tawbi, H.A.; Burgess, M.; Bolejack, V.; Van Tine, B.A.; Schuetze, S.M.; Hu, J.; D’Angelo, S.; Attia, S.; Riedel, R.F.; Priebat, D.A.; et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017, 18, 1493–1501. [Google Scholar] [CrossRef]
- Movva, S.; Mehren, M.V.; Handorf, E.A.; Morgan, J.A.; Nathenson, M.; Thornton, K.A.; Tetzlaff, E.D.; Barker, E.; Thibodeau, L.; Harley, A.C.; et al. SAR-096: A phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS). J. Clin. Oncol. 2020, 38, 11544. [Google Scholar] [CrossRef]
- Chi, Y.; Fang, Z.; Hong, X.; Yao, Y.; Sun, P.; Wang, G.; Du, F.; Sun, Y.; Wu, Q.; Qu, G.; et al. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clin. Cancer Res. 2018, 24, 5233–5238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beird, H.C.; Wu, C.C.; Ingram, D.R.; Wang, W.L.; Alimohamed, A.; Gumbs, C.; Little, L.; Song, X.; Feig, B.W.; Roland, C.L.; et al. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Mol. Case Stud. 2018, 4, a002386. [Google Scholar] [CrossRef] [Green Version]
- Hepler, C.; Vishvanath, L.; Gupta, R.K. Sorting out adipocyte precursors and their role in physiology and disease. Genes Dev. 2017, 31, 127–140. [Google Scholar] [CrossRef] [Green Version]
- Li, F.; Song, J.; Zhang, Y.; Wang, S.; Wang, J.; Lin, L.; Yang, C.; Li, P.; Huang, H. LINT-Web: A Web-Based Lipidomic Data Mining Tool Using Intra-Omic Integrative Correlation Strategy. Small Methods 2021, 5, e2100206. [Google Scholar] [CrossRef] [PubMed]
- Ben-Sahra, I.; Howell, J.J.; Asara, J.M.; Manning, B.D. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 2013, 339, 1323–1328. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hoxhaj, G.; Hughes-Hallett, J.; Timson, R.C.; Ilagan, E.; Yuan, M.; Asara, J.M.; Ben-Sahra, I.; Manning, B.D. The mTORC1 Signaling Network Senses Changes in Cellular Purine Nucleotide Levels. Cell Rep. 2017, 21, 1331–1346. [Google Scholar] [CrossRef] [Green Version]
- Patra, K.C.; Hay, N. The pentose phosphate pathway and cancer. Trends Biochem. Sci. 2014, 39, 347–354. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tian, N.; Liu, Q.; Li, Y.; Tong, L.; Lu, Y.; Zhu, Y.; Zhang, P.; Chen, H.; Hu, L.; Meng, J.; et al. Transketolase Deficiency in Adipose Tissues Protects Mice from Diet-Induced Obesity by Promoting Lipolysis. Diabetes 2020, 69, 1355–1367. [Google Scholar] [CrossRef]
- Shantz, L.M.; Talalay, P.; Gordon, G.B. Mechanism of inhibition of growth of 3T3-L1 fibroblasts and their differentiation to adipocytes by dehydroepiandrosterone and related steroids: Role of glucose-6-phosphate dehydrogenase. Proc. Natl. Acad. Sci. USA 1989, 86, 3852–3856. [Google Scholar] [CrossRef] [Green Version]
- Charytonowicz, E.; Terry, M.; Coakley, K.; Telis, L.; Remotti, F.; Cordon-Cardo, C.; Taub, R.N.; Matushansky, I. PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J. Clin. Investig. 2012, 122, 886–898. [Google Scholar] [CrossRef]
- Horvai, A.E.; Schaefer, J.T.; Nakakura, E.K.; O’Donnell, R.J. Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. Mod. Pathol. 2008, 21, 517–524. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wagner, K.D.; Benchetrit, M.; Bianchini, L.; Michiels, J.F.; Wagner, N. Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) is highly expressed in liposarcoma and promotes migration and proliferation. J. Pathol. 2011, 224, 575–588. [Google Scholar] [CrossRef] [PubMed]
- Tontonoz, P.; Singer, S.; Forman, B.M.; Sarraf, P.; Fletcher, J.A.; Fletcher, C.D.; Brun, R.P.; Mueller, E.; Altiok, S.; Oppenheim, H.; et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. USA 1997, 94, 237–241. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, Y.J.; Yu, D.B.; Kim, M.; Choi, Y.L. Adipogenesis induces growth inhibition of dedifferentiated liposarcoma. Cancer Sci. 2019, 110, 2676–2683. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Demetri, G.D.; Fletcher, C.D.; Mueller, E.; Sarraf, P.; Naujoks, R.; Campbell, N.; Spiegelman, B.M.; Singer, S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA 1999, 96, 3951–3956. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Debrock, G.; Vanhentenrijk, V.; Sciot, R.; Debiec-Rychter, M.; Oyen, R.; Van Oosterom, A. A phase II trial with rosiglitazone in liposarcoma patients. Br. J. Cancer 2003, 89, 1409–1412. [Google Scholar] [CrossRef] [Green Version]
- Xiao, Y.; Ma, D.; Yang, Y.S.; Yang, F.; Ding, J.H.; Gong, Y.; Jiang, L.; Ge, L.P.; Wu, S.Y.; Yu, Q.; et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 2022, 32, 477–490. [Google Scholar] [CrossRef]
- Hall, Z.; Chiarugi, D.; Charidemou, E.; Leslie, J.; Scott, E.; Pellegrinet, L.; Allison, M.; Mocciaro, G.; Anstee, Q.M.; Evan, G.I.; et al. Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma. Hepatology 2021, 73, 1028–1044. [Google Scholar] [CrossRef]
- Yachida, S.; Mizutani, S.; Shiroma, H.; Shiba, S.; Nakajima, T.; Sakamoto, T.; Watanabe, H.; Masuda, K.; Nishimoto, Y.; Kubo, M.; et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat. Med. 2019, 25, 968–976. [Google Scholar] [CrossRef]
- Braas, D.; Ahler, E.; Tam, B.; Nathanson, D.; Riedinger, M.; Benz, M.R.; Smith, K.B.; Eilber, F.C.; Witte, O.N.; Tap, W.D.; et al. Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment. Cancer Discov. 2012, 2, 1109–1117. [Google Scholar] [CrossRef]
- Patt, A.; Demoret, B.; Stets, C.; Bill, K.L.; Smith, P.; Vijay, A.; Patterson, A.; Hays, J.; Hoang, M.; Chen, J.L.; et al. MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models. Cancers 2020, 12, 2157. [Google Scholar] [CrossRef] [PubMed]
- Bandu, R.; Mok, H.J.; Kim, K.P. Phospholipids as cancer biomarkers: Mass spectrometry-based analysis. Mass Spectrom. Rev. 2018, 37, 107–138. [Google Scholar] [CrossRef] [PubMed]
- Du, W.; Jiang, P.; Mancuso, A.; Stonestrom, A.; Brewer, M.D.; Minn, A.J.; Mak, T.W.; Wu, M.; Yang, X. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat. Cell Biol. 2013, 15, 991–1000. [Google Scholar] [CrossRef]
- Xu, I.M.; Lai, R.K.; Lin, S.H.; Tse, A.P.; Chiu, D.K.; Koh, H.Y.; Law, C.T.; Wong, C.M.; Cai, Z.; Wong, C.C.; et al. Transketolase counteracts oxidative stress to drive cancer development. Proc. Natl. Acad. Sci. USA 2016, 113, E725–E734. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, S.; Wang, H.; Li, Y.; Xie, Y.; Huang, C.; Zhao, H.; Miyagishi, M.; Kasim, V. Transcription Factor YY1 Promotes Cell Proliferation by Directly Activating the Pentose Phosphate Pathway. Cancer Res. 2018, 78, 4549–4562. [Google Scholar] [CrossRef] [Green Version]
- Ying, H.; Kimmelman, A.C.; Lyssiotis, C.A.; Hua, S.; Chu, G.C.; Fletcher-Sananikone, E.; Locasale, J.W.; Son, J.; Zhang, H.; Coloff, J.L.; et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149, 656–670. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, H.; Yuan, M.; Seitzer, P.; Ludwigsen, S.; Asara, J.M. IsoSearch: An Untargeted and Unbiased Metabolite and Lipid Isotopomer Tracing Strategy from HR-LC-MS/MS Datasets. Methods Protoc. 2020, 3, 54. [Google Scholar] [CrossRef] [PubMed]
- Leek, J.T.; Johnson, W.E.; Parker, H.S.; Jaffe, A.E.; Storey, J.D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012, 28, 882–883. [Google Scholar] [CrossRef] [Green Version]
Characteristics | WDLPS (N = 6) | DDLPS (N = 7) |
---|---|---|
n (%) | n (%) | |
Age | ||
18–30 | 0 (0) | 1 (14) |
31–40 | 0 (0) | 1 (14) |
41–50 | 0 (0) | 1 (14) |
51–60 | 4 (67) | 3 (43) |
61–70 | 2 (33) | 0 (0) |
71–80 | 0 (0) | 1 (14) |
Gender | ||
Female | 5 (83) | 3 (43) |
Male | 1 (17) | 4 (57) |
Primary/Recurrent | ||
Primary | 1 (17) | 3 (43) |
Recurrent | 5 (83) | 4 (57) |
Previous surgery | ||
0 | 1 (17) | 3 (43) |
1 | 2 (33) | 1 (14) |
2 | 0 (0) | 2 (29) |
≥3 | 3 (50) | 1 (14) |
Other treatment prior to surgery | ||
None | 5 (83) | 3 (43) |
Targeted therapy | 1 (17) | 1 (14) |
Chemotherapy +Targeted therapy | 0 (0) | 1 (14) |
Chemotherapy +Radiation therapy +Targeted therapy +Immunotherapy | 0 (0) | 2 (29) |
FNCLCC grade | ||
I | 6 (100) | 0 (0) |
II | 0 (0) | 4 (57) |
III | 0 (0) | 3 (43) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Song, Z.; Wang, S.; Lu, L.; Xu, J.; Zhou, Q.; Lu, W.; Tong, H.; Zhang, Y.; Liu, W.; Wang, Z.; et al. Lipidomics and Transcriptomics Differ Liposarcoma Differentiation Characteristics That Can Be Altered by Pentose Phosphate Pathway Intervention. Metabolites 2022, 12, 1227. https://doi.org/10.3390/metabo12121227
Song Z, Wang S, Lu L, Xu J, Zhou Q, Lu W, Tong H, Zhang Y, Liu W, Wang Z, et al. Lipidomics and Transcriptomics Differ Liposarcoma Differentiation Characteristics That Can Be Altered by Pentose Phosphate Pathway Intervention. Metabolites. 2022; 12(12):1227. https://doi.org/10.3390/metabo12121227
Chicago/Turabian StyleSong, Zhengqing, Shuaikang Wang, Lili Lu, Jingshen Xu, Qiwen Zhou, Weiqi Lu, Hanxing Tong, Yong Zhang, Wenshuai Liu, Zhiming Wang, and et al. 2022. "Lipidomics and Transcriptomics Differ Liposarcoma Differentiation Characteristics That Can Be Altered by Pentose Phosphate Pathway Intervention" Metabolites 12, no. 12: 1227. https://doi.org/10.3390/metabo12121227